NEW YORK (TheStreet) -- Shares of BioScrip Inc.(BIOS) - Get Report are down 6.57% to $5.83 after the company reported a net loss of $28.3 million, or a loss of 42 cents a share for the 2014 third quarter, coming up short of analysts' estimates of 2 cents, according to Reuters.

The pharmacy and home health services provider reported a non-GAAP net loss from continuing operations for the 2014 third quarter of $28.3 million, or a loss of 42 cents per share, compared to net income of $1.6 million, or 1 cent per share in the prior year period.

The company incurred a charge in the third quarter of $23.1 million in its Infusion segment for bad debt and contractual reserves that represents the amount above the segment's historical experience prior to the disruption from the acquisition of the HomeChoice and CarePoint businesses.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

"These disruptions are essentially behind us," CEO Rick Smith said in the earnings conference call.

Additionally, total revenue for the third quarter was $244 million, compared to $190.6 million for the same period a year ago.

Image placeholder title

BIOS

data by

YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.